Krystal Biotech (KRYS) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on August 3, 2026.
Q2 2026
EPS
$1.79
est $1.91
-6.5%
Revenue
$119M
est $121M
-1.5%
Krystal Biotech missed Q2 on both lines, but VYJUVEK's 24% revenue growth and a slate of pipeline readouts coming in the next 12 to 18 months signal the gene therapy company is ready to transition from single-product star to multi-product powerhouse.
Mentioned: KRYS